Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

ESMO Open

article

S. Ochsenreither¹  W.M. Fiedler⁴  G.D. Conte⁵  M. Macchini⁵  I. Matos⁶  B. Habel⁷  I. Ahrens-Fath⁷  F. Raspagliesi⁸  D. Lorusso⁸  U. Keilholz¹  C. Rolling⁴  M. Kebenko⁴  K.F. Klinghammer¹  O. Saavedra⁶  H. Baumeister⁷  A. Zurlo⁷  E. Garralda⁶ 

[1] Charité Comprehensive Cancer Center;Charité, Department of Hematology;German Cancer Consortium;University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center;Fondazione IRCCS San Raffaele Hospital;Vall d’Hebron University Hospital and Institute of Oncology;Glycotope GmbH;Fondazione IRCCS Istituto Nazionale dei Tumori;Berlin Institute of Health at Charité – Universitätsmedizin Berlin

关键词: phase I;    monoclonal antibody;    EGFR;    TA-MUC1;    colorectal cancer;    lung cancer;   

DOI  :  10.1016/j.esmoop.2022.100447

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) antibody in refractory solid tumors.Patients and methods Initially the study enrolled primary phase (PP) patients with EGFR-positive metastatic solid tumors, for whom no standard treatment was available. Patients received gatipotuzumab administered at 1400 mg every 2 weeks, 6 weeks after the start of the glyco-optimized anti-EGFR antibody tomuzotuximab at 1200 mg every 2 weeks. As this regimen was proven safe, enrollment continued in an expansion phase (EP) of patients with refractory metastatic colorectal cancer, non-small-cell lung cancer, head and neck cancer and breast cancer. Tomuzotuximab and gatipotuzumab were given at the same doses and gatipotuzumab treatment started 1 week after the first dose of the anti-EGFR antibody. Additionally, investigators could use a commercial anti-EGFR antibody in place of tomuzotuximab.Results A total of 52 patients were enrolled, 20 in the PP and 32 in the EP. The combined treatment was well tolerated and no dose-limiting toxicity was observed in the whole study, nor related serious adverse event or death. Preliminary activity of the combination was observed, with one and four RECIST partial responses in the PP and EP, all in colorectal cancer patients. The trial was accompanied by a comprehensive translational research program for identification of biomarkers, including soluble TA-MUC1 (sTA-MUC1) in serum. In the EP, patients with baseline sTA-MUC1 levels above the median appeared to have improved progression-free survival and overall survival.Conclusions Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination.

【 授权许可】

CC BY|CC BY-NC-ND